Delving into the Latest Updates on Aripiprazole/Sertraline Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Aripiprazole/sertraline, Sertraline/aripiprazole

Target

5-HT1A receptor x 5-HT2A receptor x D2 receptor x D3 receptor x SERT

Action

agonists, antagonists, inhibitors

Mechanism

5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists), 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D2 receptor agonists(Dopamine D2 receptor agonists)

+ [2]

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Depressive Disorder, Major

Originator Organization

Otsuka Holdings Co., Ltd.

Active Organization-

Inactive Organization

Otsuka Pharmaceutical Co., Ltd.

Otsuka Holdings Co., Ltd.

Drug Highest PhaseDiscontinuedNDA/BLA

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC17H18Cl3N

InChIKeyBLFQGGGGFNSJKA-XHXSRVRCSA-N

CAS Registry79559-97-0

View All Structures (2)

A Single-center, Open-label, Randomized, Two-treatment, Two-period Crossover Trial to Investigate Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults

To investigate the bioequivalence of aripiprazole between administration of one ASC-01 tablet (aripiprazole 3 mg/sertraline 100 mg combination drug) and concomitant administration of one aripiprazole 3-mg tablet and two sertraline 50-mg tablets (Cohort 1).
To investigate food effect on plasma pharmacokinetics of aripiprazole and sertraline by single oral administration of ASC-01 under a fasting or fed condition (Cohort 2).

Start Date21 Nov 2017

Sponsor / Collaborator

Otsuka Pharmaceutical Co., Ltd.

JPRN-jRCT2080222363

/ CompletedPhase 3

A Multicenter, Randomized, Double-blind Trial to Assess the Efficacy and Safety of ASC-01 in Patients with Major Depressive Disorder

Start Date25 Feb 2014

Sponsor / Collaborator

Otsuka Pharmaceutical Co., Ltd.

NCT02046564

/ CompletedPhase 3

A Multicenter, Randomized, Double-blind Trial to Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder

To evaluate the efficacy and the safety of ASC-01 (aripiprazole/sertraline combination) compared to sertraline monotherapy in patients with major depressive disorders who have responded incompletely to sertraline monotherapy.

Start Date01 Feb 2014

Sponsor / Collaborator

Otsuka Pharmaceutical Co., Ltd.

100 Clinical Results associated with Aripiprazole/Sertraline Hydrochloride

Login to view more data

100 Translational Medicine associated with Aripiprazole/Sertraline Hydrochloride

Login to view more data

100 Patents (Medical) associated with Aripiprazole/Sertraline Hydrochloride

Login to view more data

5

Literatures (Medical) associated with Aripiprazole/Sertraline Hydrochloride

01 Nov 2002·The Plant JournalQ1 · BIOLOGY

The plant disease resistance gene Asc‐1 prevents disruption of sphingolipid metabolism during AAL‐toxin‐induced programmed cell death

Q1 · BIOLOGY

Article

Author: Stefka D. Spassieva ; Jacques Hille ; Jonathan E. Markham

SummaryThe nectrotrophic fungus Alternaria alternata f.sp. lycopersici infects tomato plants of the genotype asc/asc by utilizing a host‐selective toxin, AAL‐toxin, that kills the host cells by inducing programmed cell death. Asc‐1 is homologous to genes found in most eukaryotes from yeast to humans, suggesting a conserved function. A yeast strain with deletions in the homologous genes LAG1 and LAC1 was functionally complemented by Asc‐1, indicating that Asc‐1 functions in an analogous manner to the yeast homologues. Examination of the yeast sphingolipids, which are almost absent in the lag1Δlac1Δ mutant, showed that Asc‐1 was able to restore the synthesis of sphingolipids. We therefore examined the biosynthesis of sphingolipids in tomato by labeling leaf discs with l‐[3‐3H]serine. In the absence of AAL‐toxin, there was no detectable difference in sphingolipid labeling between leaf discs from Asc/Asc or asc/asc leaves. In the presence of pathologically significant concentrations of AAL‐toxin however, asc/asc leaf discs showed severely reduced labeling of sphingolipids and increased label in dihydrosphingosine (DHS) and 3‐ketodihydrosphingosine (3‐KDHS). Leaf discs from Asc/Asc leaves responded to AAL‐toxin treatment by incorporating label into different sphingolipid species. The effects of AAL‐toxin on asc/asc leaflets could be partially blocked by the simultaneous application of AAL‐toxin and myriocin. Leaf discs simultaneously treated with AAL‐toxin and myriocin showed no incorporation of label into sphingolipids or long‐chain bases as expected. These results indicate that the presence of Asc‐1 is able to relieve an AAL‐toxin‐induced block on sphingolipid synthesis that would otherwise lead to programmed cell death.

01 Feb 1996·Experimental Cell Research

A Novel Recognition Site on Laminin for the α3β1 Integrin

Article

Author: Amy P.N. Skubitz ; Sugit Pattaramalai ; Keith M. Skubitz

Synthetic peptide GD-2 is a sequence of amino acids derived from the carboxy-terminal long arm of the A chain of laminin. Previous studies have shown that peptide GD-2 promotes the adhesion of human squamous cell carcinoma (SCC) cells as well as a variety of other cell lines. In this study, we attempted to identify the receptor that SCC cells use to adhere to peptide GD-2. Monoclonal antibodies (mAbs) against a human SCC cell line were generated. One of these mAbs, ASC-1, bound to the surface of SCC cells as determined by flow cytometry. This mAb inhibited SCC cell adhesion to peptide GD-2 and laminin, but not fibronectin or type IV collagen, suggesting that mAb ASC-1 binds to the SCC receptor for the peptide GD-2 sequence of laminin. MAb ASC-1 immunoprecipitated a complex composed of two components of 135 and 116 kDa. Immunoadsorption of ASC-1-binding material from the SCC cell extract by incubation with mAb ASC-1 resulted in the removal of the alpha 3 beta 1 integrin from the extract. Immunohistochemical staining of tissue from a normal human tongue and from a patient with SCC of the tongue revealed that mAb ASC-1 stained the surface of epithelial cells that were in contact with the basement membrane, as well as those cells located two to three layers above the basement membrane. This mAb also stained blood vessels in the squamous tissue. This staining pattern was identical to that observed when the same tissues were stained by a mAb against the alpha 3 integrin subunit. In summary, by use of a new mAb, ASC-1, that recognizes the alpha 3 beta 1 integrin, we have determined that the alpha 3 beta 1 integrin mediates SCC cell adhesion to the peptide GD-2 sequence within laminin.

01 Sep 1991·American journal of veterinary research

Influence of sedative and anesthetic agents on intradermal skin test reactions in dogs.

Article

Author: Eicker, S W ; Moriello, K A

To determine the effects of 9 sedative/anesthetic drug protocols on intradermal skin testing, an experimental state of type-I hypersensitivity was created. Intradermal skin tests were performed on 6 dogs, using positive and negative controls and a series of tenfold dilutions of Asc-1 allergen prior to drug administration. Approximately 4 hours later, the dogs were given 1 of the following drugs: acepromazine (low dose and high dose); ketamine hydrochloride with diazepam; thiamylal; oxymorphone; halothane; methoxyflurane; or isoflurane. The intradermal skin test then was repeated, and was scored objectively and subjectively. Objective scores were unaffected by any of the drugs. Subjective scores were affected in that acepromazine decreased wheal size and the induration of the intradermal skin test reaction sites.

100 Deals associated with Aripiprazole/Sertraline Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Aripiprazole/Sertraline Hydrochloride	-	-

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Depressive Disorder, Major	NDA/BLA	-	Otsuka Holdings Co., Ltd.	-
Depressive Disorder, Major	NDA/BLA	-	Otsuka Holdings Co., Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03342963 (CTgov)	Phase 1	-	74	aripiprazole+sertraline+ASC-01 (ASC-01)	ptdpjksfgz(sfqwcrcjaj) = sdedpcypha kcrfgizcog (blztothuld, tvxkvuvnxk - zuofwhaada) View more	-	03 May 2021
				Aripiprazole+Sertraline (Aripiprazole/Sertraline Concomitant)	ptdpjksfgz(sfqwcrcjaj) = xutczexjzg kcrfgizcog (blztothuld, rxszjyoyih - xkgrgxfkos) View more
NCT02046564 (CTgov)	Phase 3	Depressive Disorder, Major	412	ASC-01 (ASC-01)	yiroxhpjaj(oqmughwoyo) = rjmggpfacz gowfcusqoe (bfqyyfwymg, eexacyxwbr - jjiiaytqsc) View more	-	21 May 2018
				Placebo (Placebo)	yiroxhpjaj(oqmughwoyo) = idoxfdisff gowfcusqoe (bfqyyfwymg, bluvwdfbxy - awewjkswau) View more